Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Bioasis
Deal Size : Undisclosed
Deal Type : Termination
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Bioasis
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Biodexa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 13, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Biodexa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Panobinostat lactate,Lomustine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Panobinostat lactate,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Midatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG Study
Details : The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering
Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million
Details : The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 18, 2020
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering
Details : MTX110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Medulloblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2020
CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
Details : MTX110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : Gelclair
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : PharPoint Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gelclair is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stomatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2018
Lead Product(s) : Gelclair
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : PharPoint Research
Deal Size : Inapplicable
Deal Type : Inapplicable